Sandbox GGC11: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==5CEQ DLK in complex with inhibitor 50F (2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile)== | ==5CEQ DLK in complex with inhibitor 50F (2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile)== | ||
<StructureSection load='5ceq' size='340' side='right'caption='[[5ceq]], [[Resolution|resolution]] 1.91Å' scene=''> | <StructureSection load='5ceq' size='340' side='right'caption='[[5ceq]], [[Resolution|resolution]] 1.91Å' scene=''> | ||
5CEQ is a MAP3K12 protein | 5CEQ is a MAP3K12 protein from homo sapiens. It plays a role in the MAPK Cascade pathway mostly by interacting with the JNKs, SAPKs, and ERKs which are part of part of the MAP kinases. Since some of the MAP kinases are involved with the central nervous system signaling, it has been shown that DLK also plays a role in protection of neurons when inhibited by 50F. | ||
== Function == | == Function == | ||
| Line 9: | Line 8: | ||
Neuron degenerative diseases such as Parkinson’s, and Alzheimer. | Neuron degenerative diseases such as Parkinson’s, and Alzheimer. | ||
== Relevance == | == Relevance == | ||
This protein will help us understand more about the physiology of degenerative diseases, which will lead to making more medicine that could possibly slow the deterioration process, or even cure the diseases. | |||
== Structural highlights == | |||
<scene name='78/781195/00ligand/1'>50F</scene> | |||
<scene name='78/781195/01dfg_active_site/1'>active site</scene> | |||
<scene name='78/781195/03asp161/1'>ASP161</scene> | |||
</StructureSection> | </StructureSection> | ||
Gene: MAP3K12 | |||
Related proteins: 5CEO, 5CEN, Q12852 | |||
Ligand: 50F | |||
== References == | == References == | ||
1. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y, Ma C, Scearce-Levie K, Ghosh AS, Shin YG, Solanoy H, Wang J, Wang B, Yin J, Siu M, Lewcock JW. Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). J Med Chem. 2015 Oct 2. PMID:26431428 doi:http://dx.doi.org/10.1021/acs.jmedchem.5b01072 | 1. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y, Ma C, Scearce-Levie K, Ghosh AS, Shin YG, Solanoy H, Wang J, Wang B, Yin J, Siu M, Lewcock JW. Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). J Med Chem. 2015 Oct 2. PMID:26431428 doi:http://dx.doi.org/10.1021/acs.jmedchem.5b01072 | ||